

March 30, 2026

Subject: Invitation to 2026 Annual General Meeting of Shareholders

To: Shareholders of Winnergy Medical Public Company Limited

- Enclosure:
1. The 2025 One Report and 2025 Financial Statements in QR Code format and instructions on QR Code usage.
 2. Information of individuals nominated for appointment as board members to replace the directors who retired by rotation
 3. Name-list and profile of auditors and audit fee in 2026
 4. Details of Independent Directors for Shareholder Proxy Appointment and Director Qualifications
 5. Company's Article of Association related to shareholder meetings
 6. Documents and evidence required for meeting attendees to register, proxy voting procedures, registration steps, voting and vote counting methods in electronic Annual General Meetings (E-AGM).
 7. Proxy forms in Form A, Form B, and Form C.
 8. User manual for using the meeting system via electronic media (Inventech Connect).
 9. Notice of Personal Data Processing

The Board of Directors of Winnergy Medical Public Company Limited ("Company") resolved to hold the 2026 Annual General Meeting of Shareholders on April 30, 2026, at 10.00 a.m. via an electronic media platform (E-AGM) in accordance with the criteria, procedures, and conditions as prescribed by law, excluding shareholders from attending the meeting in person to consider various agenda items as follows:

Agenda 1 To acknowledge the Company group's operating results for the year 2025

Fact and rationale: The company has prepared the annual report for the year 2025, which is presented in the format of the 56-1 One report for the year 2025 of the company in the form of a QR code. This report has been sent to the shareholders along with the invitation letter for this meeting, as provided in Enclosure 1 and presented to the shareholders at the meeting for acknowledgment.

Opinion of the Board: The Board of Directors has considered the matter and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders to acknowledge the Company group's operating results for the year 2025.

Vote for resolution: This agenda item is for acknowledgement; no voting is required.

Agenda 2 To consider and approve the financial statements for the year ended December 31, 2025

Fact and rationale: In accordance with Section 112 of Public Limited Companies Act, B. E. 2535 (and amendments) (“Public Limited Companies Act”) and Clause No.39 of Articles of Association, prescribing that the Company’s Board of Directors shall have the balance sheet or financial statements and income statement prepared, as of the date of the Company’s end of fiscal year proposed to the shareholders in the Annual General Meeting of Shareholders for consideration.

The Company has prepared its annual financial statements for the year ending December 31, 2025. These financial statements have been audited and certified by the Company’s certified public accountant, ANS Audit Co., Ltd. The Audit Committee and the Board of Directors have reviewed the financial statements and agreed that they are accurate and according to financial reporting standards. Details can be found in the 2025 56-1 One Report, Section 3: Financial Statements, as well as in the 2025 annual financial statements, which are provided in QR Code format. Instructions for using the QR Code are included in the attached document (Enclosure 1).

Opinion of the Board: The Board of Directors has considered the matter and deemed it appropriate to propose the 2025 Annual General Meeting of Shareholders to approve the Company’s financial statements for the year ended December 31, 2025, which have been audited by the external auditor and considered by the Audit Committee and the Board of Directors.

Vote for resolution: This agenda requires a majority vote of the shareholders attending the Meeting and casting their votes.

Agenda 3 To consider and approve the allocation of profit as legal reserve and the distribution of dividend payment for the operating results for the year 2025.

Fact and rationale: **(1) Allocation of Net Profit to Legal Reserve**

In accordance with Section 116 of Public Limited Companies Act, B. E. 2535 (and amendments) (“Public Limited Companies Act”) and Clause No.45 of the Company’s Articles of Association, prescribing that “The Company shall allocate some amount of its annual net profit as legal reserve for not less than 5% of its annual net profit , deducted by the accrued accumulative loss (if any) until this reserve amount will be not less than 10% of its registered capital”

In 2025, the Company's net profit received from the operating performance as per separate financial statements for the year ended December 31, 2025, was THB 13,063,307.96 It was considered as appropriate to propose to the Meeting to approve for allocation of net profit from the operating performance in the year 2025 as legal reserve of THB 653,165.40 (not less than 5% of annual net profit in 2025) with the details as follows:

| Item | 2024 | 2025 (Proposal year) |
|---|---------------|-------------------------|
| 1. Registered capital (Baht) | 200,000,000 | 200,000,000 |
| 2. Net profit in accordance with separate financial statements (Baht) | 25,827,688.36 | 13,063,307.96 |
| 3. Deduction from legal reserve (Baht) | 1,291,384.42 | 653,165.40 |
| 4. Net profit in accordance with separate financial statements (after reserve) (Baht) | 24,536,303.94 | 12,410,142.56 |
| 5. Legal reserve calculated as % of net profit as per separate financial statements | 5.00% | 5.00% |
| 6. Legal accumulative reserve profit as % of registered capital | 8.00% | 8.00% |
| 7. Legal reserve retained earnings stated in (Baht) | 16,007,301.40 | 16,660,466.80 |

(2) Dividend Payment for the 2025 Operating Results

Furthermore, to be in line with Section 115 of Public Limited Companies Act, and Clause No.44 of the Company's Articles of Association, prescribing that "The Company is strictly prohibited to pay the dividend fund from other kind of fund out of profit. In case of the Company's accumulative loss, dividend payment is not allowed". In addition, the Company has its policy to pay the dividend to shareholders at the rate of not less than 40% of the remaining net profit from deduction of all kinds of reserves as regulated by law and the Company's Articles of Association, based on net profit from separate financial statement. The dividend payment may be changed. It is subject to the Company's operating plans, financial status, liquidity, business expansion plans, any future necessities and properness, having no significant impacts on the Company and its subsidiaries' normal operations as the Company's Board of Directors and/or shareholders seen it appropriate. The Company's Board of Directors considered the dividend payment, mainly based on the Shareholder's

interests and propose to the shareholders' meeting for approval, except interim dividend payment.

In 2025, the Company's net profit from operating performance in line with separate financial statements for the year ended December 31, 2025 (after reserve deduction) was THB 12,410,142.56. The Board of Directors deemed it appropriate to propose for approval for dividend payment, based on the Company's 2025 operating performance to shareholders at the rate of THB 0.0125 per share in the total amount of THB 5,000,000, or figured as 40.29% of remaining net profit from reserve deduction.

Comparative Information on Dividend Payments:

| Description of Dividend Payment | 2024 | 2025 (Proposal Year) |
|--|---------------|-------------------------|
| 1. Net profit as per separate financial statements (after reserve) (Baht) | 24,536,303.94 | 12,410,142.56 |
| 2. 40% of net profit as per separate financial statements (after reserve) (Baht) | 9,721,419.52 | 4,964,057.02 |
| 3. Total amount of dividend payment (Baht) | 9,900,000.00 | 5,000,000.00 |
| 4. Dividend per share (Baht: Share) | 0.02475 | 0.0125 |
| 5. Dividend payment rate per remaining net profit from reserve deduction (%) | 40.35 | 40.29 |
| 6. Total number of shares entitles for receipt of dividend payment (Share) | 400,000,000 | 400,000,000 |
| 7. Par value of share (Baht: Share) | 0.50 | 0.50 |

In this regard, The Company's allocation of dividend payment shall be based on the proportion as regulated in the Company's policy of dividend payment.

Opinion of the Board:

The Board of Directors proposes that the 2026 Annual General Meeting of Shareholders approve the allocation of a legal reserve of 653,165.40 Baht, allocating legal reserve of 653,165.40 Baht, and approve a dividend payment of 0.0125 Baht per share. The record

date for eligible shareholders is March 17, 2026, with payment scheduled for May 25, 2026. The dividend payment is subject to shareholder approval.

Vote for resolution: This agenda requires a majority vote of the shareholders attending the Meeting and casting their votes.

Agenda 4 To consider and approve the appointment of directors in replacement of those who must retire by rotation

Fact and rationale: In accordance with Section 71 of Public Limited Companies Act, and Clause No.17 of the Company's Articles of Association, prescribing that for each time of the Annual General Meeting of Shareholders, it is regulated that one-third (1/3) of the total number of directors at that moment shall be retired. In case that the number of directors cannot be one-third (1/3), the number of retired directors shall be almost close to one-third (1/3). The director to be retired in the first and second year after company registration shall draw lots. For later years, the director taking the position for the longest term shall be the retired director.

At the 2026 Annual General Meeting of Shareholders, 3 directors will be retired as follows:

- (1) Asst. Prof. Dr. Terdsak Rojsurakitti Independent Director
 - Chairman of the Board
 - Chairman of the Good Corporate Governance and Sustainability Committee
 - Chairman of the Nomination and Remuneration Committee
- (2) Mr. Nattaphol Vimolchalao Independent Director
 - Member of the Audit Committee
- (3) Mr. Tanakorn Vidhayasirinun Director

The Nomination and Remuneration Committee has thoroughly reviewed and screened the proposed candidates and thinks that the individuals nominated have been considered through the Company's established procedures. They possess the required qualifications in accordance with relevant regulations and are suitable for the Company's business operations. Furthermore, they do not have any prohibited characteristics that would disqualify them from being appointed as directors, as specified by the Securities and Exchange Commission and the Stock Exchange of Thailand.

Additionally, the nominated individuals are qualified, knowledgeable, capable, and experienced, and will benefit the Company's operations. Asst. Prof. Dr. Terdsak Rojsurakitti and Mr. Nattaphol Vimolchalao, who are proposed for re-election as Independent Directors for another term, have been duly considered by the Board of Directors. The Board thinks that the nominated individuals possess qualifications in accordance with the relevant laws and regulations governing independent directors, are capable of performing their duties and expressing opinions independently, and have served as Independent Directors of the Company for a continuous period not exceeding nine (9) years from the date of their initial appointment.

The Board of Directors has considered and fully agrees with the opinion of the Nomination and Remuneration Committee and, therefore, recommends that the shareholders approve the reappointment of the three directors for another term.

Details of the nominated individuals to replace the directors retiring by rotation are provided in Attachment 2.

In accordance with good corporate governance principles, the Company had invited shareholders to propose qualified candidates for nomination as directors in advance, from November 3, 2025, to January 31, 2026, through the channels and criteria disclosed on the Company's website. No shareholders submitted agenda items or nominated any individuals during this period.

Opinion of the Board: The Board of Directors has considered the matter and deemed it appropriate to propose the 2026 Annual General Meeting of Shareholders to approve the election of directors to replace the directors who retired by rotation to be reelected.

Vote for resolution: This agenda requires a majority vote of the shareholders attending the Meeting and casting their votes.

Agenda 5 To consider and approve the remuneration of the directors for the ended December 31, 2026

Fact and rationale: In accordance with Section 90 of Public Limited Company Act B.E.2535 (and amendments) and Clause No.22 of the Company's Articles of Association, it is prescribed that the Company's directors are entitled for receiving remunerations in form of prize reward, meeting allowance, gratuity, bonus or other remunerations as the shareholders' meeting consideration with resolution by number of vote of not less than two-thirds (2/3) of total number of attending shareholders' votes. The remuneration may be fixed or provided as

some specific criteria for some periods or validity until the shareholders meeting's resolution for change. The remuneration shall not affect director rights appointed by the Company's employee or staff for receiving remunerations or benefits as the Company's employee or staff.

In this regard, the Nomination and Remuneration Committee considered and reviewed the determination of remuneration for the Company's directors and sub-committee for the year 2026, based on the Company's operating performance, business size, director's duties and responsibilities and overall economic situation which the rate of remuneration is appropriate, comparatively to remuneration of any companies in the same industry and almost same size as the company. Therefore, it is deemed appropriate to propose the 2026 director remuneration with details as follows:

| Director | Position | Meeting Allowance (Baht/Meeting/Person) ⁽¹⁾ | |
|-------------------------------------|----------|---|-------------------------|
| | | 2025 | 2026 (Proposed Year) |
| Board of Directors | Chairman | 30,000 | 30,000 |
| | Member | 15,000 | 15,000 |
| Audit Committee | Chairman | 20,000 | 20,000 |
| | Member | 15,000 | 15,000 |
| Other sub-committees ⁽²⁾ | Chairman | 15,000 | 15,000 |
| | Member | 10,000 | 10,000 |

Remark :

- (1) Any management, consultant, employee, or the major shareholder's representative in the Company's Board of Director are not entitled for remunerations as committee or sub-committee.
- (2) other sub-committees are referred to as Nomination and Remuneration Committee, Executive Committee, Risk Management Committee and Corporate Governance and Sustainability Committee.

Other monetary remuneration and bonuses:

In 2025: In addition to the above-mentioned remuneration details, the Company's Board of Directors does not receive any additional benefits beyond the specified remuneration. Due to the Company does not have a policy for providing remuneration in forms other than monetary types, apart from meeting allowances.

In 2026: In addition to the above-mentioned remuneration details, the Company's Board of Directors does not receive any additional benefits beyond the specified remuneration. Due to the Company does not have a policy for providing remuneration in forms other than monetary types, apart from meeting allowances.

Non-monetary remuneration and other benefits:

In 2025: The Board of Directors is entitled to receive benefits according to the Company's regulations, such as assistance funds in cases where a director's parents are passing away or in situations where a director passes away, etc.

In 2026: The Board of Directors is entitled to receive benefits according to the Company's regulations, such as assistance funds in cases where a director's parents are passing away or in situations where a director passes away, etc.

Opinion of the Board: The Board of Directors deems it appropriate to propose that the shareholders approve the determination of directors' remuneration for 2026. The Nomination and Remuneration Committee has thoroughly reviewed this proposed remuneration, which has been approved by the Board of Directors.

Vote for resolution: This agenda item requires not less than two-third of all votes of the shareholders attending the Meeting.

Agenda 6 To consider and approve the appointment of auditor and fix his/her remuneration for the year ended December 31, 2026

Fact and rationale: In accordance with Section 120 of Public Limited Companies Act B.E.2535, prescribing that "The Annual General Meeting of Shareholders shall appoint the Company's auditor and determine the audit fee each year. Previous auditor can be re-appointed." According to Clause No.36 of the Company's Articles of Association, it is regulated that the Annual General Meeting of Shareholders shall appoint the Company's auditor and determine the audit fee each year.

The Audit Committee has considered the performance of auditor of the Company for the year 2025 along with the qualifications as specified. It found that ANS Audit Company Limited performed its duties satisfactorily according to auditing standards and provided beneficial opinions to the company. The auditor possesses complete qualifications, has good knowledge and understanding of the group's business, and has no relationships or conflicts of interest with the company, its subsidiaries, management, major shareholders, or

related parties. Furthermore, the auditor has sufficient independence to audit and express opinions on the company's financial statements. Given these factors, it is deemed appropriate to propose that ANS Audit Company Limited, a licensed auditor approved by the Securities and Exchange Commission, continue to serve as the company's auditor for the fiscal year 2026.

Opinion of the Board: The Board of Directors deems it appropriate to propose to the Shareholders' Meeting for approval the appointment of auditors from ANS Audit Company Limited as the company's auditors for the fiscal year 2026. The list of nominated auditors is as follows:

| Auditor Name | Certified Public Accountant Number | Number of Year Providing Audit Services for the Company |
|---------------------------------|---|--|
| (1) Mr. Sathien Vongsnan | 3495 | |
| (2) Mr.Vichai Rujitanon | 4054 | - |
| (3) Miss Kulthida Phasurakul | 5946 | - |
| (4) Mr.Yutthapong Cheumuangphan | 9445 | - |
| (5) Miss Atchara Suknaibaibun | 4642 | 1 year |
| (6) Miss Patcharee Siriwongsin | 9037 | - |

By designating one of the auditors to perform the audit. and express opinions on the Company's financial statements for the year 2026. In the event that the auditors listed above are unable to perform their duties, ANS Audit Company Limited is authorized to appoint another certified public accountant of ANS Audit Co., Ltd. to perform duties on their behalf.

Auditors listed above Have qualifications that do not conflict with the regulations of the Stock Exchange of Thailand and does not have any relationship or interest with the company, subsidiaries, executives, major shareholders or those related to such persons in any way Therefore, they are independent in auditing and expressing opinions on the company's financial statements.

It is also deemed appropriate to propose that the shareholders approve the audit fee for 2026 for the Company and its one subsidiary, A New Day Co., Ltd., which uses the same

audit firm as the Company. The total audit fee amounts to 2,000,000 Baht per year. Key information for consideration is as follows

| Auditor's Remuneration for the Company | 2025 | 2026 (Proposal Year) |
|---|------------------|---------------------------------|
| 1. Audit Fee | 2,070,000 | 2,000,000 |
| 2. Non-Audit Fee | -none- | -none- |
| Total | 2,070,000 | 2,000,000 |

In addition, the Board of Directors will ensure that the financial statements are prepared within the specified timeframe.

The background information and work experience of each auditor are provided in Enclosure 3.

Vote for resolution: This agenda requires a majority vote of the shareholders attending the Meeting and casting their votes.

Agenda 7 To consider other agenda

Fact and rationale: Other Agendas will be opened for shareholders' inquiries, discussion and/or suggestion given to the Company's Board of Directors and/or administrative department for business operation, apart from matters proposed in agendas for consideration. In the event that it is shareholders' intention for giving consideration and resolution in other matters , besides agenda specified in the invitation notice for meeting , provisions of laws pursuant to Section 105 , second paragraph of Public Limited Company Act B.E.2535 prescribing that "After the meeting' s completion of consideration in first paragraph, the total number of shareholders of not less than one- third of total number of shares sold shall propose to the Meeting to consider other matters , apart from matters in agendas in invitation notice for meeting" shall be applied.

Opinion of the Board: The Board of Directors deemed it appropriate to open this Agenda for shareholders' inquiry and/or opinion other matters without voting for resolution. In case of shareholders' request for consideration and resolution, Section 105, second paragraph as above-mentioned shall be applied.

Therefore, the company would like to invite all shareholders to attend the 2026 Annual General Meeting of Shareholder on April 30, 2026, at 10:00 a.m. This meeting will be held exclusively through electronic media (E-AGM)

with no physical location or meeting room provided. The agenda for the meeting is as detailed above, and the record date for shareholders eligible to attend the 2026 Annual General Meeting of Shareholder is set for March 17, 2026.

For shareholders who wish to attend the meeting in person, please register to attend the meeting through the following link: <https://con.inventech.co.th/WINMED987426R/#/homepage> or scan the QR code below to access the system. The registration system will be available from April 20, 2026, at 08:30 a.m., and will close on April 30, 2026, until the meeting adjourned.



Shareholders wishing to appoint a proxy to attend the meeting on their behalf, please follow the procedures for attending the shareholder meeting through Electronic Annual General Meeting (E-AGM) as per Enclosure 6 along with attaching the necessary identification documents (for shareholders) or the proxy letter and accompanying documents (for proxy appointments) as specified in Documents and evidence required for meeting attendees for verification of attendance rights. For the E-AGM, shareholders can appoint any individual to attend the meeting on their behalf or appoint Mr. Chanat Sorakraikitikul or Dr. Renu Ubol, who are independent directors of the Company, as their proxy. Details of Independent Directors serving as proxies are provided in Enclosure 3. For shareholder convenience, the company has sent Proxy Appointment Forms, Form B, along with this meeting invitation. Please fill in the details and sign the Proxy Appointment Form (Enclosure 7) or download Proxy Appointment Forms, Form B, from www.winmed.com and submit all documents to the Company by April 28, 2026, through the following channels:

Email: comsec@winnergy.co.th or ir@winnergy.co.th
Postal: Winnergy Medical Public Company Limited
Company Secretary Department
634/4 Soi Ramkhamhaeng 39 (Theplila 1)
Pracha Uthit Road, Wang Thong Lang Sub-District,
Wang Thong Lang District, Bangkok, Thailand 10310
Tel : 02- 725-0888 Ext. 720, 702

Once the Company has received complete documentation as required, it will proceed to review the documents to confirm the right to attend the meeting. Upon successful verification of the right, the Company will

-Translation-



appoint Inventech Systems (Thailand) Company Limited, a certified provider of the Company's E-AGM meeting system accredited by the Electronic Transactions Development Agency, as the entity responsible for distributing the usernames, passwords, and weblinks for accessing the E-AGM meeting system to you via the email address you have provided to the Company.

In conducting shareholder meetings via electronic media, the Company will record the proceedings in the form of video conferencing. Additionally, the company will collect, use, and disclose personal information of shareholders in order to fulfill its duties as prescribed by law and for the benefit of providing services to shareholders attending the meeting. Shareholders will be protected under the personal data protection policy or privacy notice as available on the Company's website. All shareholders are asked to consider the personal data processing notification for the Company's shareholders, with details as provided in Enclosure 8.

Please be informed accordingly.

Sincerely yours,

A handwritten signature in blue ink, appearing to read 'Terdsak Rojsurakitti'.

Asst. Prof. Dr. Terdsak Rojsurakitti
Chairman of the Board of Directors
Winergy Medical Public Company Limited